恩替卡韦联合聚乙二醇干扰素及序贯乙肝疫苗接种提高HBsAg清除率:一项随机对照概念验证研究
该随机对照概念验证试验纳入111例经恩替卡韦治疗后HBV DNA<20 IU/mL且定量HBsAg<3000 IU/mL的慢性乙肝患者,按1:1:1分为恩替卡韦+序贯疫苗接种组、恩替卡韦+同步疫苗接种组和恩替卡韦单药对照组。序贯疫苗组和同步疫苗组不良事件发生率显著高于对照组,但严重不良事件无显著差异。
要点
- 恩替卡韦联合peg-IFN alfa-2a后序贯HBV疫苗可显著提高第100周HBsAg清除率。
- 同步疫苗接种方案未显示显著优于恩替卡韦单药。
- 联合方案不良事件更常见,但严重不良事件无显著增加。
核心结论
- 恩替卡韦联合peg-IFN alfa-2a治疗后序贯强化HBV疫苗接种,较恩替卡韦单药显著提高第100周HBsAg清除机会。
研究设计与样本
- 随机对照概念验证试验,111例经恩替卡韦治疗达到HBV DNA<20 IU/mL且定量HBsAg<3000 IU/mL的患者按1:1:1随机分组。
主要发现
- 三组严重不良事件发生率分别为2.7%、5.4%和2.7%,差异无统计学意义(P=1.00)。
关键数值与推荐
- 序贯疫苗组方案:恩替卡韦+peg-IFN alfa-2a 180 µg每周一次共48周,并于第52、56、60、76周接种20 µg HBsAg疫苗。
- 同步疫苗组方案:恩替卡韦+peg-IFN alfa-2a,并于第4、8、12、28周接种HBV疫苗。
- 主要终点为第100周HBsAg清除率。
临床怎么用
- 对于恩替卡韦治疗后HBV DNA<20 IU/mL且定量HBsAg<3000 IU/mL的慢性乙肝患者,可考虑peg-IFN alfa-2a联合序贯HBV疫苗接种以提高HBsAg清除机会。
- 采用该联合方案时需注意不良事件监测,尽管严重不良事件未见显著增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B surface antigen (HBsAg) seroclearance is considered a functional cure for patients with chronic hepatitis B, but is rarely achievable with oral nucleos(t)ide analogues alone. We conducted a randomized controlled proof-of-concept trial to evaluate the impact of adding pegylated interferon (peg-IFN) alfa-2a plus sequential or concomitant hepatitis B virus (HBV) vaccination. METHODS: A total of 111 patients who achieved serum HBV DNA <20 IU/mL and quantitative HBsAg <3000 IU/mL with entecavir were randomly assigned (1:1:1) to the E + sVIP group (entecavir + peg-IFN alfa-2a [180 µg every week over 48 weeks] plus sequential HBV vaccination [20 µg of HBsAg on weeks 52, 56, 60, and 76]), the E + cVIP group (entecavir + peg-IFN alfa-2a + concomitant HBV vaccination [weeks 4, 8, 12, and 28]), or the control group (entecavir only). The primary endpoint was HBsAg seroclearance at week 100, and secondary endpoints included safety. RESULTS: No differences in baseline quantitative HBsAg were observed among the groups. The E + sVIP group in the intention-to-treat analysis showed a significantly higher chance of HBsAg seroclearance during week 100 than the control group (16.2% vs 0%; P = .025), but the E + cVIP group (5.4%) failed to reach a significant difference (P = .54). Adverse events were significantly more frequent in the E + sVIP (81.1%) and E + cVIP group (70.3%) than the control group (2.7%) (both P < .0001). However, the frequency of serious adverse events did not differ significantly among the 3 groups (2.7%, 5.4%, and 2.7%, respectively; P = 1.00). CONCLUSIONS: Entecavir plus an additional peg-IFN alfa-2a treatment followed by sequential HBV vaccination under an intensified schedule significantly increases the chance of HBsAg seroclearance compared to entecavir alone. CLINICAL TRIALS REGISTRATION: NCT02097004.
引用
- Lee JH, Lee YB, Cho EJ, et al. Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study. Clin Infect Dis. 2021. PMID: 32556157. doi:10.1093/cid/ciaa807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。